Cargando…

The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers

OBJECTIVE: In our recent study, non-Gaussianity of heart rate variability (λ(25s)), an indicator of sympathetic nerve activity, did not change during two-day treatment with the angiotensin II type 1 receptor blocker (ARB) azilsartan. Coadministration of calcium channel blockers (CCBs) might affect t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Michio, Isobe-Sasaki, Yukako, Sato, Ryo, Miura, Toshiyuki, Mizuno, Masashi, Ono, Minamo, Kiyono, Ken, Yamamoto, Yoshiharu, Hayano, Junichiro, Ohte, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437324/
https://www.ncbi.nlm.nih.gov/pubmed/30915878
http://dx.doi.org/10.1177/1470320319839525
_version_ 1783406942038786048
author Fukuda, Michio
Isobe-Sasaki, Yukako
Sato, Ryo
Miura, Toshiyuki
Mizuno, Masashi
Ono, Minamo
Kiyono, Ken
Yamamoto, Yoshiharu
Hayano, Junichiro
Ohte, Nobuyuki
author_facet Fukuda, Michio
Isobe-Sasaki, Yukako
Sato, Ryo
Miura, Toshiyuki
Mizuno, Masashi
Ono, Minamo
Kiyono, Ken
Yamamoto, Yoshiharu
Hayano, Junichiro
Ohte, Nobuyuki
author_sort Fukuda, Michio
collection PubMed
description OBJECTIVE: In our recent study, non-Gaussianity of heart rate variability (λ(25s)), an indicator of sympathetic nerve activity, did not change during two-day treatment with the angiotensin II type 1 receptor blocker (ARB) azilsartan. Coadministration of calcium channel blockers (CCBs) might affect the study results. METHODS: In this subanalysis, 20 patients with chronic kidney disease (14 men; age 61±15 years) were divided into three groups: patients with coadministration of L-type CCB, patients without coadministration of CCB, and patients with coadministration of sympathoinhibitory (L/T- or L/T/N-type) CCB. λ(25s) was calculated separately in daytime and nighttime. RESULTS: Daytime λ(25s) at baseline was higher in patients with L-type CCB coadministration (0.62±0.18, n = 5) compared with those without CCB (0.49±0.13, n = 11) and those with sympathoinhibitory CCB (0.46±0.06, n = 4). The relationship between the changes in daytime λ(25s) and systolic blood pressure was positive in patients with L-type CCB coadministration, whereas the relationship was inverse in the other two groups. A larger decrease in daytime λ(25s) was shown in patients with L-type CCB coadministration compared with those in the other two groups. CONCLUSIONS: CCBs, as well as diuretics, are recommended as second-line antihypertensive agents. Our results suggested that ARBs can overwhelm the activation of sympathetic nerve activity stimulated by coadministration of L-type CCBs.
format Online
Article
Text
id pubmed-6437324
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64373242019-04-03 The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers Fukuda, Michio Isobe-Sasaki, Yukako Sato, Ryo Miura, Toshiyuki Mizuno, Masashi Ono, Minamo Kiyono, Ken Yamamoto, Yoshiharu Hayano, Junichiro Ohte, Nobuyuki J Renin Angiotensin Aldosterone Syst Original Article OBJECTIVE: In our recent study, non-Gaussianity of heart rate variability (λ(25s)), an indicator of sympathetic nerve activity, did not change during two-day treatment with the angiotensin II type 1 receptor blocker (ARB) azilsartan. Coadministration of calcium channel blockers (CCBs) might affect the study results. METHODS: In this subanalysis, 20 patients with chronic kidney disease (14 men; age 61±15 years) were divided into three groups: patients with coadministration of L-type CCB, patients without coadministration of CCB, and patients with coadministration of sympathoinhibitory (L/T- or L/T/N-type) CCB. λ(25s) was calculated separately in daytime and nighttime. RESULTS: Daytime λ(25s) at baseline was higher in patients with L-type CCB coadministration (0.62±0.18, n = 5) compared with those without CCB (0.49±0.13, n = 11) and those with sympathoinhibitory CCB (0.46±0.06, n = 4). The relationship between the changes in daytime λ(25s) and systolic blood pressure was positive in patients with L-type CCB coadministration, whereas the relationship was inverse in the other two groups. A larger decrease in daytime λ(25s) was shown in patients with L-type CCB coadministration compared with those in the other two groups. CONCLUSIONS: CCBs, as well as diuretics, are recommended as second-line antihypertensive agents. Our results suggested that ARBs can overwhelm the activation of sympathetic nerve activity stimulated by coadministration of L-type CCBs. SAGE Publications 2019-03-27 /pmc/articles/PMC6437324/ /pubmed/30915878 http://dx.doi.org/10.1177/1470320319839525 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Fukuda, Michio
Isobe-Sasaki, Yukako
Sato, Ryo
Miura, Toshiyuki
Mizuno, Masashi
Ono, Minamo
Kiyono, Ken
Yamamoto, Yoshiharu
Hayano, Junichiro
Ohte, Nobuyuki
The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
title The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
title_full The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
title_fullStr The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
title_full_unstemmed The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
title_short The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
title_sort angiotensin ii type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437324/
https://www.ncbi.nlm.nih.gov/pubmed/30915878
http://dx.doi.org/10.1177/1470320319839525
work_keys_str_mv AT fukudamichio theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT isobesasakiyukako theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT satoryo theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT miuratoshiyuki theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT mizunomasashi theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT onominamo theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT kiyonoken theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT yamamotoyoshiharu theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT hayanojunichiro theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT ohtenobuyuki theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT fukudamichio angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT isobesasakiyukako angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT satoryo angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT miuratoshiyuki angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT mizunomasashi angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT onominamo angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT kiyonoken angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT yamamotoyoshiharu angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT hayanojunichiro angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers
AT ohtenobuyuki angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers